PRFX vs. BPTH, ATNF, QLGN, INM, ALLR, PXMD, PBLA, ADXS, GLMD, and BDRX
Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Bio-Path (BPTH), 180 Life Sciences (ATNF), Qualigen Therapeutics (QLGN), InMed Pharmaceuticals (INM), Allarity Therapeutics (ALLR), PaxMedica (PXMD), Panbela Therapeutics (PBLA), Ayala Pharmaceuticals (ADXS), Galmed Pharmaceuticals (GLMD), and Biodexa Pharmaceuticals (BDRX). These companies are all part of the "pharmaceutical preparations" industry.
PainReform (NASDAQ:PRFX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
Bio-Path received 279 more outperform votes than PainReform when rated by MarketBeat users. However, 100.00% of users gave PainReform an outperform vote while only 55.42% of users gave Bio-Path an outperform vote.
PainReform's return on equity of 0.00% beat Bio-Path's return on equity.
37.3% of PainReform shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 3.1% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Bio-Path had 5 more articles in the media than PainReform. MarketBeat recorded 10 mentions for Bio-Path and 5 mentions for PainReform. PainReform's average media sentiment score of 0.46 beat Bio-Path's score of 0.11 indicating that PainReform is being referred to more favorably in the media.
PainReform has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.
Bio-Path has a consensus price target of $40.00, indicating a potential upside of 1,769.16%. Given Bio-Path's higher probable upside, analysts plainly believe Bio-Path is more favorable than PainReform.
Summary
PainReform beats Bio-Path on 8 of the 12 factors compared between the two stocks.
Get PainReform News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PainReform Competitors List
Related Companies and Tools
